Cargando…

Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy

Axillary staging is 1 of the major issues of current breast cancer management after neoadjuvant systemic therapy (NST). Sentinel lymph node biopsy (SLNB) is an option for clinically node negative patients. Axillary reverse mapping (ARM) was introduced to identify and preserve the lymphatic drainage...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasdoven, Ilhan, Balbaloglu, Hakan, Erdemir, Rabiye Uslu, Bahadir, Burak, Guldeniz Karadeniz, Cakmak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803496/
https://www.ncbi.nlm.nih.gov/pubmed/36596061
http://dx.doi.org/10.1097/MD.0000000000032545
_version_ 1784861899457822720
author Tasdoven, Ilhan
Balbaloglu, Hakan
Erdemir, Rabiye Uslu
Bahadir, Burak
Guldeniz Karadeniz, Cakmak
author_facet Tasdoven, Ilhan
Balbaloglu, Hakan
Erdemir, Rabiye Uslu
Bahadir, Burak
Guldeniz Karadeniz, Cakmak
author_sort Tasdoven, Ilhan
collection PubMed
description Axillary staging is 1 of the major issues of current breast cancer management after neoadjuvant systemic therapy (NST). Sentinel lymph node biopsy (SLNB) is an option for clinically node negative patients. Axillary reverse mapping (ARM) was introduced to identify and preserve the lymphatic drainage from the arm. The aim of the presented study is to employ triple mapping (radiocolloid, blue dye and indocyanine green [ICG]) to assess the crossover rate and metastatic involvement of ARM nodes after NST. Clinically node positive patients before NST who were converted to N0 and scheduled for targeted axillary dissection were included. sentinel lymph node (SLN) mapping was performed via dual agent mapping. ICG was used for ARM procedure. Blue, hot and fluorescent nodes and lymphatics were visualized in the axilla using infrared camera system and dual opto-nuclear probe (Euoroprobe3). Fifty-two patients underwent targeted axillary dissection and ARM procedures 12 out of whom had axillary node dissection. 45 of the 52 patients had at least 1 hot or blue SLN identified intraoperatively. Of these, 61.5% cases had hot SLNs, 42.3% had hot and blue, 15.4% had hot/blue/fluorescent, 7.7% had blue/fluorescent, 6 11.5% had hot/fluorescent and 7 13.5% had only clipped nodes. The overall identification rate of ARM-nodes by means of ICG technique was 86.5%. Overall crossover of ARM nodes with SLNs was determined in 36.5%. The ICG intensity was found to be higher in both hot and blue SLNS (8 out of 18 ICG positive cases, 44.4%). In 3 of 52 patients (5.7%) metastatic SLNs were hot or blue but fluorescent which predicts metastatic involvement of the ARM-nodes. More than 1-third of the patients revealed a crossover between arm and breast draining nodes. The higher observed rate of overlap might partially explain why more patients develop clinically significant lymphedema after NST even after sentinel lymph node biopsy alone. The triple mapping provides valuable data regarding the competency of lymphatic drainage and would have the potential to serve selecting patients for lymphovenous by-pass procedures at the index procedure. NST reduces the metastatic involvement of the ARM nodes. However, conservative axillary staging with sparing ARM nodes after NST necessitates further studies with larger sample size and longer follow-up.
format Online
Article
Text
id pubmed-9803496
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98034962023-01-03 Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy Tasdoven, Ilhan Balbaloglu, Hakan Erdemir, Rabiye Uslu Bahadir, Burak Guldeniz Karadeniz, Cakmak Medicine (Baltimore) 5750 Axillary staging is 1 of the major issues of current breast cancer management after neoadjuvant systemic therapy (NST). Sentinel lymph node biopsy (SLNB) is an option for clinically node negative patients. Axillary reverse mapping (ARM) was introduced to identify and preserve the lymphatic drainage from the arm. The aim of the presented study is to employ triple mapping (radiocolloid, blue dye and indocyanine green [ICG]) to assess the crossover rate and metastatic involvement of ARM nodes after NST. Clinically node positive patients before NST who were converted to N0 and scheduled for targeted axillary dissection were included. sentinel lymph node (SLN) mapping was performed via dual agent mapping. ICG was used for ARM procedure. Blue, hot and fluorescent nodes and lymphatics were visualized in the axilla using infrared camera system and dual opto-nuclear probe (Euoroprobe3). Fifty-two patients underwent targeted axillary dissection and ARM procedures 12 out of whom had axillary node dissection. 45 of the 52 patients had at least 1 hot or blue SLN identified intraoperatively. Of these, 61.5% cases had hot SLNs, 42.3% had hot and blue, 15.4% had hot/blue/fluorescent, 7.7% had blue/fluorescent, 6 11.5% had hot/fluorescent and 7 13.5% had only clipped nodes. The overall identification rate of ARM-nodes by means of ICG technique was 86.5%. Overall crossover of ARM nodes with SLNs was determined in 36.5%. The ICG intensity was found to be higher in both hot and blue SLNS (8 out of 18 ICG positive cases, 44.4%). In 3 of 52 patients (5.7%) metastatic SLNs were hot or blue but fluorescent which predicts metastatic involvement of the ARM-nodes. More than 1-third of the patients revealed a crossover between arm and breast draining nodes. The higher observed rate of overlap might partially explain why more patients develop clinically significant lymphedema after NST even after sentinel lymph node biopsy alone. The triple mapping provides valuable data regarding the competency of lymphatic drainage and would have the potential to serve selecting patients for lymphovenous by-pass procedures at the index procedure. NST reduces the metastatic involvement of the ARM nodes. However, conservative axillary staging with sparing ARM nodes after NST necessitates further studies with larger sample size and longer follow-up. Lippincott Williams & Wilkins 2022-12-30 /pmc/articles/PMC9803496/ /pubmed/36596061 http://dx.doi.org/10.1097/MD.0000000000032545 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5750
Tasdoven, Ilhan
Balbaloglu, Hakan
Erdemir, Rabiye Uslu
Bahadir, Burak
Guldeniz Karadeniz, Cakmak
Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
title Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
title_full Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
title_fullStr Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
title_full_unstemmed Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
title_short Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
title_sort triple mapping for axillary staging after neoadjuvant therapy: axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy
topic 5750
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803496/
https://www.ncbi.nlm.nih.gov/pubmed/36596061
http://dx.doi.org/10.1097/MD.0000000000032545
work_keys_str_mv AT tasdovenilhan triplemappingforaxillarystagingafterneoadjuvanttherapyaxillaryreversemappingwithindocyaninegreenanddualagentsentinellymphnodebiopsy
AT balbalogluhakan triplemappingforaxillarystagingafterneoadjuvanttherapyaxillaryreversemappingwithindocyaninegreenanddualagentsentinellymphnodebiopsy
AT erdemirrabiyeuslu triplemappingforaxillarystagingafterneoadjuvanttherapyaxillaryreversemappingwithindocyaninegreenanddualagentsentinellymphnodebiopsy
AT bahadirburak triplemappingforaxillarystagingafterneoadjuvanttherapyaxillaryreversemappingwithindocyaninegreenanddualagentsentinellymphnodebiopsy
AT guldenizkaradenizcakmak triplemappingforaxillarystagingafterneoadjuvanttherapyaxillaryreversemappingwithindocyaninegreenanddualagentsentinellymphnodebiopsy